THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
Open Access
- 18 November 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 40 (1) , 2-14
- https://doi.org/10.1093/alcalc/agh110
Abstract
The endogenous cannabinoid system is an ubiquitous lipid signalling system that appeared early in evolution and which has important regulatory functions throughout the body in all vertebrates. The main endocannabinoids (endogenous cannabis-like substances) are small molecules derived from arachidonic acid, anandamide (arachidonoylethanolamide) and 2-arachidonoylglycerol. They bind to a family of G-protein-coupled receptors, of which the cannabinoid CB1 receptor is densely distributed in areas of the brain related to motor control, cognition, emotional responses, motivated behaviour and homeostasis. Outside the brain, the endocannabinoid system is one of the crucial modulators of the autonomic nervous system, the immune system and microcirculation. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and serve as retrograde signalling messengers in GABAergic and glutamatergic synapses, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters, including dopamine. Endocannabinoids are transported into cells by a specific uptake system and degraded by two well-characterized enzymes, the fatty acid amide hydrolase and the monoacylglycerol lipase. Recent pharmacological advances have led to the synthesis of cannabinoid receptor agonists and antagonists, anandamide uptake blockers and potent, selective inhibitors of endocannabinoid degradation. These new tools have enabled the study of the physiological roles played by the endocannabinoids and have opened up new strategies in the treatment of pain, obesity, neurological diseases including multiple sclerosis, emotional disturbances such as anxiety and other psychiatric disorders including drug addiction. Recent advances have specifically linked the endogenous cannabinoid system to alcoholism, and cannabinoid receptor antagonism now emerges as a promising therapeutic alternative for alcohol dependence and relapse.Keywords
This publication has 130 references indexed in Scilit:
- Signaling pathways involved in the development of cannabinoid toleranceTrends in Pharmacological Sciences, 2004
- Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brainThe Journal of cell biology, 2003
- Cannabis and alcohol – a close friendshipTrends in Pharmacological Sciences, 2003
- Postsynaptic endocannabinoid release is critical to long-term depression in the striatumNature Neuroscience, 2002
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- The neurobiology and evolution of cannabinoid signallingPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2001
- ARE ANANDAMIDE AND CANNABINOID RECEPTORS INVOLVED IN ETHANOL TOLERANCE? A REVIEW OF THE EVIDENCEAlcohol and Alcoholism, 2000
- Anandamide suppresses nitric oxide and TNF-α responses to Theilerʼs virus or endotoxin in astrocytesNeuroReport, 1997
- The cannabinoid receptor: biochemical, anatomical and behavioral characterizationTrends in Neurosciences, 1990
- Isolation, Structure, and Partial Synthesis of an Active Constituent of HashishJournal of the American Chemical Society, 1964